- Over 180,000 U.S. and EU Patients Treated
Year-to-Date with Sovaldi or Harvoni -
- Product Sales of $8.1 billion -
- Non-GAAP EPS of $3.15 per share -
- Revised 2015 Full Year Guidance -
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results
of operations for the second quarter ended June 30, 2015. The
financial results that follow represent a year over year comparison
of second quarter 2015 to the second quarter 2014. Total revenues
were $8.2 billion in 2015 compared to $6.5 billion in 2014. Net
income was $4.5 billion or $2.92 per diluted share in 2015 compared
to $3.7 billion or $2.20 per diluted share in 2014. Non-GAAP net
income, which excludes amounts related to acquisition,
restructuring, stock-based compensation and other, was $4.8 billion
or $3.15 per diluted share in 2015 compared to $3.9 billion or
$2.36 per diluted share in 2014.
Three Months Ended Six Months Ended
June 30, June 30, (In millions, except per share
amounts) 2015 2014 2015
2014 Product sales $ 8,126 $ 6,413 $ 15,531 $ 11,284
Royalty, contract and other revenues 118 122 307
250 Total revenues $ 8,244 $ 6,535 $ 15,838
$ 11,534 Net income attributable to Gilead $ 4,492 $
3,656 $ 8,825 $ 5,883 Non-GAAP net income attributable to Gilead $
4,845 $ 3,929 $ 9,449 $ 6,417 Diluted EPS $ 2.92 $ 2.20 $
5.68 $ 3.52 Non-GAAP diluted EPS $ 3.15 $ 2.36 $ 6.08 $ 3.84
Product Sales
Total product sales for the second quarter of 2015 were $8.1
billion compared to $6.4 billion for the second quarter of 2014.
Product sales in the U.S. were $5.6 billion compared to $4.8
billion for the second quarter of 2014. In Europe, product sales
were $2.0 billion compared to $1.3 billion for the same period in
2014.
Antiviral Product Sales
Antiviral product sales increased to $7.6 billion for the second
quarter of 2015, up from $6.0 billion for the second quarter of
2014 primarily due to sales of Harvoni® (ledipasvir 90
mg/sofosbuvir 400 mg), which was approved in the U.S. and Europe in
the fourth quarter of 2014, partially offset by a decrease in sales
of Sovaldi® (sofosbuvir 400 mg) due primarily to the uptake in
Harvoni.
Other Product Sales
Other product sales, which include Letairis® (ambrisentan),
Ranexa® (ranolazine) and AmBisome® (amphotericin B liposome for
injection), were $495 million for the second quarter of 2015
compared to $401 million for the second quarter of 2014.
Operating Expenses
Three Months Ended Six Months Ended
June 30, June 30, (In millions) 2015
2014 2015 2014 Non-GAAP research
and development expenses $ 702 $ 542 $ 1,353 $ 1,100 Non-GAAP
selling, general and administrative expenses $ 761 $ 570 $ 1,361 $
1,070
Note: Non-GAAP R&D and SG&A expenses exclude amounts
related to acquisition, restructuring, stock-based compensation and
other.
During the second quarter of 2015, compared to the same period
in 2014:
- Non-GAAP research and development
(R&D) expenses increased primarily due to the continued
progression and expansion of Gilead's clinical studies,
particularly Phase 3 studies in the liver disease and oncology
areas.
- Non-GAAP selling, general and
administrative (SG&A) expenses increased primarily due to an
increase in Gilead's portion of the branded prescription drug fee
along with growth and the geographic expansion in its
business.
Cash, Cash Equivalents and Marketable
Securities
As of June 30, 2015, Gilead had $14.7 billion of cash, cash
equivalents and marketable securities compared to $14.5 billion as
of March 31, 2015. During the second quarter of 2015, Gilead
generated $5.7 billion in operating cash flow, utilized $900
million to repurchase 9 million shares under the $15.0 billion
share repurchase plan approved in January 2015 and $3.9 billion to
retire 46 million warrants related to the 2016 convertible debt. At
June 30, 2015, approximately 9 million warrants remain outstanding.
Gilead also paid its first cash dividend of $633 million, or $0.43
per share, during the second quarter of 2015.
Revised 2015 Full Year
Guidance
Gilead updated its full year 2015 guidance, which it initially
provided on February 3, 2015, updated on April 30, 2015, and
further revised on July 28, 2015.
(In millions, except percentages and per share amounts)
Initially Provided
February 3, 2015
Updated
April 30, 2015
Updated
July 28, 2015
Net Product Sales $26,000 - $27,000 $28,000 - $29,000
$29,000 - $30,000 Non-GAAP* Product Gross Margin 87%
- 90% 87% - 90% 88% - 90% R&D expenses $3,000 - $3,300 $3,000 -
$3,300 $2,800 - $3,000 SG&A expenses $3,000 - $3,300 $3,000 -
$3,300 $3,000 - $3,200 Effective Tax Rate 18.0% - 20.0% 18.0% -
20.0% 17.0% - 18.0% Diluted EPS Impact of
Acquisition-Related, Restructuring, Stock-Based Compensation
Expenses and Other $0.82 - $0.87 $0.82 - $0.87 $0.82 - $0.87
* Non-GAAP product gross margin, R&D and SG&A expenses and
effective tax rate exclude amounts related to acquisition,
restructuring, stock-based compensation and other.
Corporate Highlights
- Announced the signing of a definitive
agreement to acquire EpiTherapeutics, a privately-held Danish
company. EpiTherapeutics generated a library of first-in-class,
selective small molecule inhibitors of epigenetic regulation of
gene transcription, in particular histone demethylases.
- Announced that the company’s Board of
Directors declared a quarterly cash dividend of $633 million or
$0.43 per share of common stock and paid on June 29, 2015 to all
stockholders of record as of the close of business on the record
date of June 16, 2015. This was the first quarterly dividend
declared under the Board's dividend program announced on February
3, 2015.
Product & Pipeline Updates
Announced by Gilead During the Second Quarter of 2015
Include:
Antiviral Program
- Announced that Gilead submitted a New
Drug Application (NDA) to the U.S. Food and Drug Administration
(FDA) for two doses of an investigational fixed-dose combination of
emtricitabine and tenofovir alafenamide (F/TAF) (200/10 mg and
200/25 mg) for the treatment of HIV-1 infection in adults and
pediatric patients age 12 years and older, in combination with
other HIV antiretroviral agents. Under the Prescription Drug User
Fee Act, the FDA has set a target action date
of April 7, 2016.
- This was Gilead's second F/TAF-based
NDA submitted to the FDA for review. In November 2014, Gilead
filed an NDA for an investigational once-daily single tablet
regimen containing elvitegravir 150 mg, cobicistat 150 mg,
emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF).
The FDA has set a target action date of November 5,
2015.
- Announced that Gilead’s Marketing
Authorization Application (MAA) for two doses of F/TAF (200/10 mg
and 200/25 mg) was fully validated and under evaluation by the
European Medicines Agency. The data included in the application
support the use of F/TAF for the treatment of HIV-1 infection in
adults in combination with other HIV antiretroviral agents.
- Gilead's MAA for E/C/F/TAF was
validated on December 23, 2014.
- Presented data at the 50th Annual
Meeting of the European Association for the Study of the Liver
including:
- Positive results from two studies
evaluating the safety and efficacy of investigational uses of
sofosbuvir-based regimens in HCV-infected patients with genotypes
2, 3, 4 and 5. Results from the BOSON study of sofosbuvir in
combination with ribavirin or with pegylated interferon and
ribavirin demonstrated high cure rates across all patients with
genotypes 2 and 3. Separately, results from a Phase 2 study
demonstrated the safety and efficacy of ledipasvir/sofosbuvir in
patients with genotypes 4 or 5 infection.
- Positive results from several Phase 2
clinical studies evaluating investigational uses of
ledipasvir/sofosbuvir and other sofosbuvir-based regimens for the
treatment of HCV infection in patients with advanced liver disease,
including patients with decompensated cirrhosis, patients with
fibrosing cholestatic hepatitis C (a rare and severe form of the
disease following liver transplantation) and patients with portal
hypertension.
- Positive pre-clinical data and results
from Phase 1 and Phase 2 studies supporting the development of an
investigational all-oral, pan-genotypic regimen of sofosbuvir, the
investigational NS5A inhibitor velpatasvir (formerly GS-5816) and
GS-9857, an investigational NS3/4A protease inhibitor. In
pre-clinical studies, GS-9857 demonstrated similarly potent
antiviral activity against HCV replicons of all tested genotypes
(1-6), as well as an improved resistance profile compared to other
HCV protease inhibitors. In a healthy volunteer study, GS-9857
demonstrated a favorable pharmacokinetic profile. Data from a
three-day monotherapy study also demonstrated that GS-9857 was
well-tolerated for HCV patients with genotypes 1, 2, 3 and 4 at the
100 mg dose.
Oncology Program
- Announced positive results from the
Phase 3 clinical Study 119 of an investigational use of Zydelig®
(idelalisib) in combination with ofatumumab in previously-treated
patients with chronic lymphocytic leukemia. In Study 119, there was
a 73-percent reduction in the risk of disease progression or death
in patients receiving Zydelig in combination with ofatumumab
compared to ofatumumab alone. These results were presented at the
51st Annual Meeting of the American Society of Clinical
Oncology.
Conference Call
At 4:30 p.m. Eastern Time today, Gilead's management will host a
conference call and a simultaneous webcast to discuss results from
its second quarter 2015 as well as provide a general business
update. The live webcast of the call can be accessed at the
company's Investors page at www.gilead.com/investors. Please connect to the
company's website at least 15 minutes prior to the start of the
call to ensure adequate time for any software download that may be
required to listen to the webcast. Alternatively, please call
1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial
the conference ID 73361664 to access the call.
A replay of the webcast will be archived on the company's
website for one year, and a phone replay will be available
approximately two hours following the call through July 30, 2015.
To access the phone replay, please call 1-855-859-2056 (U.S.) or
1-404-537-3406 (international) and dial the conference ID
73361664.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
Non-GAAP Financial
Information
Gilead has presented certain financial information in accordance
with U.S. generally accepted accounting principles (GAAP) and also
on a non-GAAP basis. Management believes this non-GAAP information
is useful for investors, when considered in conjunction with
Gilead's GAAP financial statements, because management uses such
information internally for its operating, budgeting and financial
planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to
supplement an understanding of Gilead's operating results as
reported under GAAP. A reconciliation between GAAP and non-GAAP
financial information is provided in the tables on pages 7 and
8.
Forward-looking
Statements
Statements included in this press release that are not
historical in nature are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Gilead cautions readers that forward-looking statements are subject
to certain risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2015
financial results; Gilead's ability to sustain growth in revenues
for its antiviral and other programs; availability of funding for
state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which
may not mirror patient demand and may cause fluctuations in
Gilead's earnings; the possibility of unfavorable results from
clinical trials involving sofosbuvir-containing products, including
the pan-genotypic regimen of sofosbuvir, velpatasvir and GS-9857;
Gilead's ability to initiate clinical trials in its currently
anticipated timeframes; the levels of inventory held by wholesalers
and retailers which may cause fluctuations in Gilead's earnings;
Gilead's ability to submit new drug applications for new product
candidates in the timelines currently anticipated; Gilead's ability
to receive regulatory approvals in a timely manner or at all, for
new and current products, including F/TAF and E/C/F/TAF; Gilead's
ability to successfully commercialize its products; the risk that
physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe
the products; the risk that estimates of patients with HCV or
anticipated patient demand may not be accurate; the risk that
private and public payers may be reluctant to provide, or continue
to provide, coverage or reimbursement for new products, including
Sovaldi and Harvoni; Gilead's ability to successfully develop its
oncology, inflammation, cardiovascular and respiratory programs,
including the compounds purchased from EpiTherapeutics; safety and
efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including the
pan-genotypic regimen of sofosbuvir, velpatasvir and GS-9857; the
potential for additional austerity measures in European countries
that may increase the amount of discount required on Gilead's
products; Gilead's ability to complete its share repurchase program
due to changes in its stock price, corporate or other market
conditions; Gilead’s ability to pay dividends under its dividend
program and the risk that its Board of Directors may reduce the
amount of the dividend; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency
exchange impact on Gilead's future revenues and pre-tax earnings;
and other risks identified from time to time in Gilead's reports
filed with the U.S. Securities and Exchange Commission (SEC). In
addition, Gilead makes estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and
related disclosures. Gilead bases its estimates on historical
experience and on various other market specific and other relevant
assumptions that it believes to be reasonable under the
circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may
differ significantly from these estimates. You are urged to
consider statements that include the words may, will, would, could,
should, might, believes, estimates, projects, potential, expects,
plans, anticipates, intends, continues, forecast, designed, goal,
or the negative of those words or other comparable words to be
uncertain and forward-looking. Gilead directs readers to its press
releases, Quarterly Report on Form 10-Q for the quarter ended March
31, 2015 and other subsequent disclosure documents filed with the
SEC. Gilead claims the protection of the Safe Harbor contained in
the Private Securities Litigation Reform Act of 1995 for
forward-looking statements.
All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and
trade names used in our business, including the following: GILEAD®,
GILEAD SCIENCES®, HARVONI®, SOVALDI®, TRUVADA®, STRIBILD®,
COMPLERA®, EVIPLERA®, VIREAD®, LETAIRIS®, RANEXA®, AMBISOME®,
ZYDELIG®, EMTRIVA®, TYBOST®, HEPSERA®, VITEKTA®, CAYSTON®,
VOLIBRIS®, and RAPISCAN®.
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered
trademark belonging to Astellas U.S. LLC. MACUGEN® is a registered
trademark belonging to Eyetech, Inc. SUSTIVA® is a registered
trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU® is a
registered trademark belonging to Hoffmann-La Roche Inc.
For more information on Gilead Sciences, Inc.,
please visit www.gilead.com or call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235).
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME
(unaudited)
(in millions, except per share
amounts)
Three Months Ended Six Months Ended
June 30, June 30, 2015 2014
2015 2014 Revenues: Product sales $ 8,126 $
6,413 $ 15,531 $ 11,284 Royalty, contract and other revenues 118
122 307 250 Total revenues 8,244
6,535 15,838 11,534 Costs and expenses: Cost
of goods sold 998 925 1,880 1,738 Research and development expenses
818 584 1,514 1,179 Selling, general and administrative expenses
812 614 1,457 1,162 Total costs and
expenses 2,628 2,123 4,851 4,079 Income
from operations 5,616 4,412 10,987 7,455 Interest expense (140 )
(102 ) (293 ) (178 ) Other income (expense), net 35 (4 ) 56
(22 ) Income before provision for income taxes 5,511 4,306
10,750 7,255 Provision for income taxes 1,014 656
1,921 1,382 Net income 4,497 3,650 8,829 5,873 Net
income (loss) attributable to noncontrolling interest 5 (6 )
4 (10 ) Net income attributable to Gilead $ 4,492 $
3,656 $ 8,825 $ 5,883 Net income per share
attributable to Gilead common stockholders - basic $ 3.05 $ 2.39 $
5.96 $ 3.83 Net income per share attributable to Gilead common
stockholders - diluted $ 2.92 $ 2.20 $ 5.68 $ 3.52 Shares used in
per share calculation - basic 1,472 1,533 1,480 1,535 Shares used
in per share calculation - diluted 1,540 1,664 1,555 1,672 Cash
dividends declared per share $ 0.43 $ — $ 0.43 $ —
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended Six Months Ended
June 30, June 30, 2015 2014
2015 2014 Cost of goods sold
reconciliation: GAAP cost of goods sold $ 998 $ 925 $ 1,880 $
1,738 Stock-based compensation expenses (3 ) (2 ) (6 ) (5 )
Acquisition related-amortization of purchased intangibles (207 )
(200 ) (413 ) (399 ) Variable interest entity consolidated costs(1)
— — 1 — Non-GAAP cost of goods sold $
788 $ 723 $ 1,462 $ 1,334
Product gross margin reconciliation: GAAP product gross
margin 87.7 % 85.6 % 87.9 % 84.6 % Acquisition related-amortization
of purchased intangibles 2.5 % 3.1 % 2.7 % 3.5 % Non-GAAP product
gross margin(2) 90.3 % 88.7 % 90.6 % 88.2 %
Research and
development expenses reconciliation: GAAP research and
development expenses $ 818 $ 584 $ 1,514 $ 1,179 Stock-based
compensation expenses (42 ) (37 ) (84 ) (71 ) Acquisition related
expenses (67 ) — (67 ) — Acquisition related-contingent
consideration remeasurement (7 ) (5 ) (10 ) (8 ) Non-GAAP research
and development expenses $ 702 $ 542 $ 1,353 $
1,100
Selling, general and administrative expenses
reconciliation: GAAP selling, general and administrative
expenses $ 812 $ 614 $ 1,457 $ 1,162 Stock-based compensation
expenses (51 ) (44 ) (98 ) (90 ) Restructuring expenses — — 2 —
Acquisition related-amortization of purchased intangibles —
— — (2 ) Non-GAAP selling, general and administrative
expenses $ 761 $ 570 $ 1,361 $ 1,070
Operating margin reconciliation: GAAP operating
margin 68.1 % 67.5 % 69.4 % 64.6 % Stock-based compensation
expenses 1.2 % 1.3 % 1.2 % 1.4 % Acquisition related expenses 0.8 %
— % 0.4 % — % Acquisition related-amortization of purchased
intangibles 2.5 % 3.1 % 2.6 % 3.5 % Acquisition related-contingent
consideration remeasurement 0.1 % 0.1 % 0.1 % 0.1 % Non-GAAP
operating margin(2) 72.7 % 71.9 % 73.6 % 69.6 %
Other
income (expense) reconciliation: GAAP other income (expense),
net $ 35 $ (4 ) $ 56 $ (22 ) Acquisition related-transaction costs
— — — (2 ) Non-GAAP other income (expense),
net $ 35 $ (4 ) $ 56 $ (24 ) Notes: Immaterial
amounts are not presented in the tables above (1) Consolidation of
a contract manufacturer
(2) Amounts may not sum due to
rounding
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION - (Continued)
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended Six Months Ended
June 30, June 30, 2015 2014
2015 2014 Effective tax rate
reconciliation: GAAP effective tax rate 18.4 % 15.2 % 17.9 %
19.1 % Acquisition related expenses/transaction costs (0.2 )% — %
(0.1 )% — % Acquisition related-amortization of purchased
intangibles (0.5 )% (0.6 )% (0.5 )% (0.9 )% Non-GAAP effective tax
rate(1) 17.7 % 14.6 % 17.3 % 18.2 %
Net income
attributable to Gilead reconciliation: GAAP net income
attributable to Gilead $ 4,492 $ 3,656 $ 8,825 $ 5,883 Stock-based
compensation expenses 71 72 140 136 Restructuring expenses — — (2 )
— Acquisition related expenses/transaction costs 67 — 67 (1 )
Acquisition related-amortization of purchased intangibles 202 196
403 391 Acquisition related-contingent consideration remeasurement
7 5 10 8 Variable interest entity consolidated costs(2) 6 —
6 — Non-GAAP net income attributable to Gilead
$ 4,845 $ 3,929 $ 9,449 $ 6,417
Diluted earnings per share reconciliation: GAAP diluted
earnings per share $ 2.92 $ 2.20 $ 5.68 $ 3.52 Stock-based
compensation expenses 0.05 0.04 0.09 0.08 Acquisition related
expenses/transaction costs 0.04 — 0.04 — Acquisition
related-amortization of purchased intangibles 0.13 0.12 0.26 0.23
Acquisition related-contingent consideration remeasurement —
— 0.01 — Non-GAAP diluted earnings per
share(1) $ 3.15 $ 2.36 $ 6.08 $ 3.84
Shares used in per share calculation (diluted)
reconciliation: GAAP shares used in per share calculation
(diluted) 1,540 1,664 1,555 1,672 Share impact of current
stock-based compensation rules — (1 ) — (1 ) Non-GAAP
shares used in per share calculation (diluted) 1,540 1,663
1,555 1,671
Non-GAAP adjustment
summary: Cost of goods sold adjustments $ 210 $ 202 $ 418 $ 404
Research and development expenses adjustments 116 42 161 79
Selling, general and administrative expenses adjustments 51 44 96
92 Other income (expense) adjustments — — — (2
) Total non-GAAP adjustments before tax 377 288 675 573 Income tax
effect (30 ) (14 ) (58 ) (38 ) Variable interest entity
consolidated costs(2) 6 — 7 — Total
non-GAAP adjustments after tax attributable to Gilead $ 353
$ 274 $ 624 $ 535 Notes: Immaterial
amounts are not presented in the tables above (1) Amounts may not
sum due to rounding (2) Consolidation of a contract manufacturer
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited)
(in millions)
June
30,
December 31, 2015 2014(1) Cash,
cash equivalents and marketable securities $ 14,667 $ 11,726
Accounts receivable, net 5,331 4,635 Inventories 2,039 1,386
Property, plant and equipment, net 1,899 1,674 Intangible assets,
net 10,660 11,073 Goodwill 1,172 1,172 Other assets 3,399
2,998 Total assets $ 39,167 $ 34,664 Current
liabilities $ 8,925 $ 5,761 Long-term liabilities 13,601 13,069
Equity component of currently redeemable convertible notes 7 15
Stockholders’ equity(2) 16,634 15,819 Total liabilities and
stockholders’ equity $ 39,167 $ 34,664 Notes:
(1) Derived from the audited consolidated
financial statements as of December 31, 2014.
(2) As of June 30, 2015, there were 1,473
million shares of common stock issued and outstanding.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in millions)
Three Months Ended Six Months Ended
June 30, June 30, 2015 2014
2015 2014 Antiviral products: Harvoni – U.S. $
2,826 $ — $ 5,842 $ — Harvoni – Europe 623 — 1,100 — Harvoni –
Other International 159 — 245 — 3,608 —
7,187 — Sovaldi – U.S. 615 3,031 1,036 5,129
Sovaldi – Europe 522 401 1,005 564 Sovaldi – Other International
154 49 222 62 1,291 3,481 2,263
5,755 Truvada – U.S. 500 399 909 767 Truvada – Europe
277 338 578 661 Truvada – Other International 72 69
133 138 849 806 1,620 1,566
Atripla – U.S. 549 578 1,043 1,068 Atripla – Europe 178 234 372 471
Atripla – Other International 55 58 101 111
782 870 1,516 1,650 Stribild – U.S. 364
230 646 417 Stribild – Europe 65 31 126 55 Stribild – Other
International 18 9 31 13 447 270
803 485 Complera / Eviplera – U.S. 207 153 370 284
Complera / Eviplera – Europe 145 132 290 241 Complera / Eviplera –
Other International 15 14 27 25 367 299
687 550 Viread – U.S. 134 117 234 198 Viread –
Europe 77 88 157 172 Viread – Other International 60 56
114 102 271 261 505 472
Other Antiviral – U.S. 8 13 22 20 Other Antiviral – Europe 7 10 14
19 Other Antiviral – Other International 1 2 2
4 16 25 38 43 Total antiviral products
– U.S. 5,203 4,521 10,102 7,883 Total antiviral products – Europe
1,894 1,234 3,642 2,183 Total antiviral products – Other
International 534 257 875 455 7,631
6,012 14,619 10,521 Other products: Letairis 176 145
327 268 Ranexa 141 123 258 234 AmBisome 103 94 188 186 Zydelig 30 —
56 — Other 45 39 83 75 495 401
912 763 Total product sales $ 8,126 $ 6,413
$ 15,531 $ 11,284
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150728006596/en/
Gilead Sciences, Inc.Robin Washington, 650-522-5688
(Investors)Patrick O'Brien, 650-522-1936
(Investors)Amy Flood, 650-522-5643
(Media)
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024